Clinical Trials on Platelet-Rich Plasma

Total 5626 results

National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Abdullah Khan

Terminated

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Washington
National Cancer Institute (NCI); SecuraBio

Terminated

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Assiut University

Unknown

Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.

New Tumor Diagnostics From Human Plasma Samples

Egypt
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic

Completed

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
The Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...

Terminated

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Millennium... and other collaborators

Active, not recruiting

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Peking University People's Hospital
The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaborators

Not yet recruiting

Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT (Haplo-HSCT)

Thrombocytopenia | Stem Cell Transplant Complications

China
The First Affiliated Hospital of Dalian Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chinese... and other collaborators

Recruiting

Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury (Circular)

Cancer Treatment Induced Thrombocytopenia

China
Institute of Hematology & Blood Diseases Hospital
Henan Cancer Hospital; Tianjin Medical University Cancer Institute and Hospital and other collaborators

Recruiting

Herombopag for Chemotherapy-induced Thrombocytopenia

Chemotherapy-induced Thrombocytopenia | Herombopag

China
Institute of Hematology & Blood Diseases Hospital
Henan Cancer Hospital; Tianjin Medical University Cancer Institute and Hospital and other collaborators

Recruiting

Avatrombopag for Chemotherapy-induced Thrombocytopenia

Chemotherapy-induced Thrombocytopenia | Avatrombopag

China
Institute of Hematology & Blood Diseases Hospital
Henan Cancer Hospital; Tianjin Medical University Cancer Institute and Hospital and other collaborators

Recruiting

Eltrombopag for Chemotherapy-induced Thrombocytopenia

Eltrombopag | Chemotherapy-induced Thrombocytopenia

China
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
St. Louis University

Completed

PFA-100 Responsive to Effect of Energy Drinks on Platelet Function

Thrombosis | Platelet Function

United States
Angde Biotech Pharmaceutical Co., Ltd.

Unknown

A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor

Chemotherapy-induced Thrombocytopenia

China
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI); Transfusion Medicine/Hemostasis...

Completed

Optimal Platelet Dose Strategy for Management of Thrombocytopenia (PLADO)

Thrombocytopenia

United States
Mayo Clinic

Active, not recruiting

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Shahid Beheshti University

Completed

High-fat Yogurt and Plasma Lipids Profile

Plasma Lipid Profile

Iran, Islamic Republic of
Rambam Health Care Campus

Completed

Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma

Classical Hodgkin Lymphoma | Nodular Sclerosis | Mixed Cellularity | Lymphocyte Depletion | Lymphocyte Rich

Israel
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia

Tumor Therapy-related Thrombocytopenia
Memorial Sloan Kettering Cancer Center
Amgen

Completed

Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

Isolated Chemotherapy-induced Thrombocytopenia

United States
University of California, San Francisco

Completed

Defibrotide TMA Prophylaxis Pilot Trial

Thrombotic Microangiopathies

United States
Karolinska Institutet
Thrasher Research Fund

Completed

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study (Neo-HAT)

Thrombocytopenia

Sweden, United States
GlaxoSmithKline

Completed

Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide

Thrombocytopaenia

United States
University of Cologne

Unknown

Screening of TMA Patients für ADAMTS13 Activity (Adamscreen) (Adamscreen)

Thrombotic Microangiopathies
Catharina Ziekenhuis Eindhoven

Completed

Platelet Function in Minimal Extracorporeal Circulation in CABG (ECCTEG)

Thrombocytopathy

Netherlands
Scientific Institute San Raffaele
Università Vita-Salute San Raffaele

Recruiting

Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD) (PASVAD)

Thrombosis | Blood Coagulation Disorder | Platelet Thrombus | Platelet Dysfunction Due to Aspirin | Failure;Ventricular

Italy
U.S. Army Medical Research and Development Command

Completed

Ascending Doses of Autologous FDP vs FFP (FDP)

Freeze Dried Plasma in Healthy Volunteers

United States
Research & Diagnostic Antibodies
National Institute of General Medical Sciences (NIGMS)

Completed

Normal Human Plasma Level of iNOS Study

Normal Human Plasma Level of iNOS

United States
The University of Hong Kong

Terminated

Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents

Gastric Ulcer Induced by Anti-platelet Agent | Duodenal Ulcer Induced by Anti-platelet Agent | OGD

China, Hong Kong
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia. (TIH-FM)

Heparin-induced Thrombocytopenia

France
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Platelet Transfusion Refractoriness | Acute Leukemia in Remission

China
Ruijin Hospital

Active, not recruiting

Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG (DACAB-GI-2)

Coronary Artery Bypass | Gastrointestinal Ulcer (Peptic) or Erosion | Anti-Platelet Therapy

China
Damian Ratano
The PSI Foundation, Ontario

Active, not recruiting

Thrombo-Elastography Guided Management of ECMO (TEGMO)

Extracorporeal Circulation of Blood; Thrombocytopenia

Canada
Weill Medical College of Cornell University
Columbia University; New York Presbyterian Hospital

Completed

A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia

Alloimmune Thrombocytopenia | Fetal Alloimmune Thrombocytopenia

United States
IRCCS Policlinico S. Matteo
GlaxoSmithKline; University of Pavia; Azienda Ospedaliera di Padova; Azienda Ospedaliera... and other collaborators

Completed

Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease

Blood Platelet Disorders

Italy
Medstar Health Research Institute
GlaxoSmithKline

Unknown

Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)

Heparin-Induced Thrombocytopenia

United States

Clinical Trials on Platelet-Rich Plasma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations